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See Article, pages 554–560Pathogenesis of intracranial hypertension in acute liver failure
(ALF) has been a subject of intense investigation and debate over
a number of years. Hyperammonemia, systemic and brain
inﬂammation, and alterations in cerebral blood ﬂow have all been
suggested as interrelated pathogenic mechanisms [1]. The
prevailing hypothesis is that increased brain ammonia results
in cytotoxic brain edema due to an increase in astrocytic gluta-
mine, which acts as an osmolyte producing accumulation of
water in the cell [2]. Cerebral hyperlactatemia has been sug-
gested to be associated with increased ICP in patients with ALF.
In fact, close correlation between increased brain lactate and
increased ICP was shown in humans with ALF [3]. The pathophys-
iological mechanism of this increase in brain lactate is not fully
understood but has been suggested to occur due to relative cere-
bral hypoperfusion, reduced cerebral oxygenation and an ammo-
nia induced inhibition of a key enzyme in the tricarboxylic acid
cycle, alpha-ketoglutarate dehydrogenase driving anaerobic
metabolism [4,5]. Arguments countering this contention are the
observations that cerebral blood ﬂow is indeed increased in late
stages of ALF, which correlates with the severity of intracranial
hypertension, a maintained lactate/pyruvate ratio, undisturbed
cerebral alpha-ketoglutarate dehydrogenase in ALF animals and
no signiﬁcant differences in brain mitochondrial complex activi-
ties [6,7]. Taken together, the studies favour the hypothesis that
the increase in brain lactate is a consequence of pathophysiologic
mechanisms rather than its cause and therefore a marker rather
than a therapeutic target. The study by Bosoi et al. questions this
hypothesis [8]. Data about brain lactate metabolism in chronic
liver disease is scarce and therefore the paper in the present issue
of the Journal adds further to the literature.
The authors of the study interpret their data to suggest that
brain lactate and not brain glutamine acts as a pivotal osmolyte
in the pathogenesis of brain edema in a chronic liver failure
animal model and therefore is a potential target for therapy.
The study was performed in 6-weeks bile duct ligated rats
(BDL) rats. BDL rats demonstrated a signiﬁcant increase in brain
lactate (p <0.001), and brain glutamine (p <0.001 and p <0.01
respectively) and de novo synthesis of brain lactate and glutamine
from 13C-labelled glucose compared with Sham rats. To
investigate the role of lactate in the physiopathology of the brainJournal of Hepatology 20
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Open access under CC BY-NC-ND license.edema, the authors administered to dichloroacetate (DCA) intra-
peritoneally, a drug that decreases lactate synthesis by shifting
lactate dehydrogenase activity from lactate to pyruvate produc-
tion. The results demonstrate that DCA treatment normalized
brain lactate levels and reduced brain water content in BDL rats
(p <0.05). Cerebral glutamine, ammonia, and liver enzymes were
not signiﬁcantly different between groups. They also used a
second intervention, a synthetic carbon, AST-120, which they
have shown in the past, reduces ammonia in a similar model. This
intervention reduced the arterial ammonia and also reduced
brain water measured by gravimetry method. Here again they
observed a diminution in the brain lactate with no changes in
the brain glutamine levels. They conclude that reduction in brain
lactate may be a potential therapeutic target.
This suggestion is provocative and requires discussion
considering the role that lactate plays as an important energy
resource for the brain [9,10]. Lactate is produced by astrocytes
as a ﬁnal product of glycolysis and is transported into the extra-
cellular space. The neurons take up this lactate via transporters
[11] and can use the lactate obtained from the astrocytes as
energy converting the lactate to pyruvate by lactate dehydroge-
nase, which then enters the tricarboxylic acid cycle [12]. The
existence of this lactate shuttle between astrocytes and neurons
is supported by a number of experimental studies [13] and has
been demonstrated in patients with traumatic brain injury [14].
During the recent past, several human and animal studies point
to the importance of brain lactate in maintaining homeostasis
[13] that require consideration to put into context the results of
Bosoi et al. [8]. Suzuki et al. [15] demonstrated the importance
of lactate in long-term memory formation and long-term poten-
tiation showing that long-term memory was impaired after the
administration of 1,4-dideoxy-1,4-imino-darabinitol [DAB], a
potent inhibitor of astrocytic glycogen phosphorylase and the
improvement by the administration of exogenous lactate.
Smith et al. showed that exogenous sodium lactate administra-
tion during exercise leads to a reduction in the glucose consump-
tion rate [16] and that the brain could use this to provide energy
as an alternative source. In an animal model of traumatic brain
injury, Chen et al. demonstrated that lactate could be used by
an injured area of the brain as energy source [17] and the
cognitive impairment during traumatic brain injury could be
improved by the administration of lactate [18]. Ichai et al.
demonstrated that the acute infusion of sodium lactate was more
effective treating the intracranial hypertension than Mannitol14 vol. 60 j 476–477
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[19]. The neuroprotective effect of lactate during hypoglycemia
or cerebral ischemia has been reported providing in vivo evidence
of the preference of the brain for lactate over glucose [20]. There-
fore, any suggestion to inhibit pathways relating to inhibition of
lactate synthesis is potentially dangerous particularly in patients
with hepatic encephalopathy and difﬁcult to envisage unless pro-
vided with very compelling data.
The main question is in relation to the end-point of this study,
brain water measurement, which many of us have used in several
papers to deﬁne potential effectiveness of a positive intervention.
Changing brain water content is possibly an important end-point
in ALF where death occurs from intracranial hypertension but the
increases in water, measured using whichever technique includ-
ing electron microscopy, is very mild in chronic liver disease and
although this may be pathophysiologically relevant, unlikely to
contribute to the syndrome of HE [21,22]. There are good data
that clearly show that brain swelling and astrocytic edema
induced by hyperammonemia or administration of lipopolysac-
charide that is indistinguishable from that observed in BDL ani-
mals does not contribute to alterations in consciousness level
or neurophysiology of the animal [21,22]. These observations
seriously question the relevance of brain water measurement
being used and end-point to suggest that an intervention such
as DCA that inhibits lactate synthesis can be a potential therapy.
We would suggest that detailed and careful neurophysiology,
neuropsychometry, histopathopathologic examination and stud-
ies of brain bioenergetics would be the ﬁrst steps required to pro-
vide relevance to the strategy proposed. Nevertheless, the data
presented by Bosoi et al. are very valuable as they provide com-
pelling evidence that the long-held view linking ammonia–gluta-
mine–brain swelling–hepatic encephalopathy hypothesis is
questionable [2,8].
In conclusion, lactate is an osmolyte used by the brain as one
of the most important energy sources. The lack of lactate cannot
be replaced by glucose as the brain is a high consumer of energy
and the substrate pool is limited. The suggestion to inhibit lactate
synthesis should be taken with caution as the lack of energy
sources could lead to a worsening of the functionality of the
brain, inducing worsening of the motor and memory deﬁcits.Conﬂict of interest
Professor Jalan is the inventor of a drug to treat hepatic enceph-
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